Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice

70Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: The tyrosine kinase inhibitor imatinib mesylate was developed as an inhibitor of the kinase activity of BCR-ABL. However, imatinib also has potent inhibitory activity against the platelet-derived growth factor receptor (PDGFR). Nilotinib is approved for treating patients with chronic myeloid leukemia showing resistance or intolerance to imatinib. Like imatinib, nilotinib selectively inhibits the tyrosine kinase activity of PDGFR. Objectives: We examined the effect of imatinib and nilotinib on acute lung injury and pulmonary fibrosis in a mouse model. Methods: Mice were treated by intratracheal instillation of bleomycin. Imatinib or nilotinib were administered by oral gavage. To study the early inflammatory and late fibrotic phases of lung injury, mice were sacrificed on days 3, 7, 14 and 21 after bleomycin instillation. Results: Histopathology showed that imatinib and nilotinib attenuated the extent of lung injury and fibrosis. The numbers of inflammatory cells and levels of IL-6, IL-1β and tumor necrosis factor-α were decreased in the imatinib and nilotinib groups on days 3 and 7. Imatinib and nilotinib therapy significantly reduced the levels of hydroxyproline on days 14 and 21, which was accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFR-β. Imatinib and nilotinib also significantly reduced the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Imatinib and nilotinib treatment also significantly inhibited the PDGF-induced proliferation of lung fibroblasts in vitro. When imatinib or nilotinib was given 7 days after the instillation of bleomycin, only nilotinib attenuated pulmonary fibrosis. Conclusions: Imatinib and nilotinib attenuated bleomycin-induced acute lung injury and pulmonary fibrosis in mice. In a therapeutic model, nilotinib showed more potent antifibrotic effects than imatinib. Copyright © 2011 S. Karger AG, Basel.

References Powered by Scopus

Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-ΔΔC</sup>T method

149991Citations
N/AReaders
Get full text

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome

11078Citations
N/AReaders
Get full text

The acute respiratory distress syndrome

4745Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors

511Citations
N/AReaders
Get full text

Idiopathic pulmonary fibrosis and lung cancer: Mechanisms and molecular targets

227Citations
N/AReaders
Get full text

Dissecting fibrosis: Therapeutic insights from the small-molecule toolbox

190Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Rhee, C. K., Lee, S. H., Yoon, H. K., Kim, S. C., Lee, S. Y., Kwon, S. S., … Kim, J. W. (2011). Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration, 82(3), 273–287. https://doi.org/10.1159/000327719

Readers over time

‘11‘12‘13‘14‘15‘17‘18‘19‘20‘21‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

55%

Researcher 7

23%

Professor / Associate Prof. 6

19%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

45%

Agricultural and Biological Sciences 6

21%

Pharmacology, Toxicology and Pharmaceut... 5

17%

Biochemistry, Genetics and Molecular Bi... 5

17%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0